论文部分内容阅读
目的探讨雷帕霉素联合I~(125)治疗晚期非小细胞肺癌患者的临床疗效。方法选取2013年1月至2014年12月间江苏省南通市第二人民医院收治的100例非小细胞肺癌患者,采用随机数表法分为观察组和对照组,每组50例。观察组患者在粒子植入治疗基础上加用雷帕霉素治疗,对照组患者采用粒子植入治疗。比较两组患者的近期疗效、卡氏体能状态评分(KPS)、不良反应情况及1年生存率。结果观察组患者的总有效率为52.0%,显著高于对照组的30.0%,差异有统计学意义(P<0.05)。治疗前两组患者的KPS评分比较,差异无统计学意义(P>0.05),治疗后观察组患者的KPS评分显著高于对照组,差异有统计学意义(P<0.05)。观察组患者的1年生存率为78.0%,显著高于对照组的64.0%,差异有统计学意义(P<0.05)。两组患者的主要不良反应均为恶心呕吐、肝肾功能异常、贫血及脱发,观察组不良反应发生率为40.0%,对照组不良反应发生率为38.0%,组间比较,差异无统计学意义(P>0.05)。结论雷帕霉素联合I~(125)治疗晚期非小细胞肺癌的疗效确切,可显著改善患者的KPS评分,延长患者的生存时间,安全性较好,值得在临床上推广和应用。
Objective To investigate the clinical efficacy of rapamycin combined with I ~ (125) in the treatment of advanced non-small cell lung cancer. Methods From January 2013 to December 2014, 100 patients with non-small cell lung cancer who were admitted to Second People’s Hospital of Nantong City, Jiangsu Province were divided into observation group and control group using random number table method, with 50 cases in each group. The patients in the observation group were treated with rapamycin on the basis of particle implantation and the patients in the control group were treated with particle implantation. The short-term efficacy, Karnofsurance status score (KPS), adverse reactions and 1-year survival rate were compared between the two groups. Results The total effective rate in observation group was 52.0%, which was significantly higher than that in control group (30.0%), the difference was statistically significant (P <0.05). There was no significant difference in KPS score between the two groups before treatment (P> 0.05). The KPS score of the observation group was significantly higher than that of the control group after treatment (P <0.05). The 1-year survival rate in observation group was 78.0%, which was significantly higher than that in control group (64.0%), the difference was statistically significant (P <0.05). The main adverse reactions in both groups were nausea and vomiting, abnormal liver and kidney function, anemia and hair loss. The incidence of adverse reactions in the observation group was 40.0% and that in the control group was 38.0%. There was no significant difference between the two groups (P> 0.05). Conclusion The combination of rapamycin and I ~ (125) is effective in treating advanced non-small cell lung cancer. It can significantly improve the KPS score, prolong the survival time of patients and have better safety. It is worth to be popularized and applied clinically.